EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Amarillo Biosciences, Inc.
(OTCBB:AMAR), maintaining its Speculative Buy rating and a 15- to ...
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Sept. 18, 2006--Dutton Associates initiates coverage of Amarillo Biosciences (OTCBB:AMAR) with a Speculative Buy and a price target of $1.90. The 18-page...
#4: AMAR News Management Team of Amarillo Biosciences, Inc., Discuss Upcoming Studies and Successful Passing of FDA's 30-day Review Process for Company's Investigational New Drug Application for Idiopathic Pulmonary Fibrosis at SmallCapVoice.com
AUSTIN, Texas--(BUSINESS WIRE)--Aug. 17, 2006--SmallCapVoice.com, Inc. today announced that a new audio interview is available at SmallCapVoice.com. The featured guests are Joseph and Marty Cummins...
AUSTIN, Texas--(BUSINESS WIRE)--Aug. 10, 2006--SmallCapVoice.com, Inc. today announced that a new audio interview is available at SmallCapVoice.com. The featured guest is Joseph Cummins, President...
Amarillo Biosciences Enters Into Agreement to Commercialize Low Dose Oral Interferon in Seven Additional SE Asian Countries
Avian Flu Fuels Interest in Low Dose Oral Interferon as Potential...
Amarillo Biosciences Issues Progress Report
Amarillo Biosciences, Inc. (OTC BB: AMAR) today issued the following progress report:
In October 2005, patients will start enrolling in our study of...
